Trials / Withdrawn
WithdrawnNCT04158700
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Phase 1b/2 Study of LY3200882 and Pembrolizumab in Patients With Advanced Cancer
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-β (TGFβ) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3200882 | LY3200882 administered orally |
| DRUG | Pembrolizumab | Pembrolizumab administered IV |
Timeline
- Start date
- 2019-12-05
- Primary completion
- 2023-05-11
- Completion
- 2023-05-11
- First posted
- 2019-11-12
- Last updated
- 2020-02-19
Locations
6 sites across 3 countries: United States, France, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04158700. Inclusion in this directory is not an endorsement.